[go: up one dir, main page]

MA24242A1 - Procede pour la preparation de nouveaux composes - Google Patents

Procede pour la preparation de nouveaux composes

Info

Publication number
MA24242A1
MA24242A1 MA24272A MA24272A MA24242A1 MA 24242 A1 MA24242 A1 MA 24242A1 MA 24272 A MA24272 A MA 24272A MA 24272 A MA24272 A MA 24272A MA 24242 A1 MA24242 A1 MA 24242A1
Authority
MA
Morocco
Prior art keywords
preparation
new compounds
therapy
compositions
novel
Prior art date
Application number
MA24272A
Other languages
English (en)
Inventor
Leroy Adams Jerry
Sisko Joseph
Peng Zhi-Qiang
Francis Gallagher Timothy
Charles Boehm Jeffrey
Kelly Osifo Irennegbe
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MA24242A1 publication Critical patent/MA24242A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Resins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)
MA24272A 1995-06-07 1996-06-06 Procede pour la preparation de nouveaux composes MA24242A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47339695A 1995-06-07 1995-06-07
US63677996A 1996-04-19 1996-04-19

Publications (1)

Publication Number Publication Date
MA24242A1 true MA24242A1 (fr) 1998-07-01

Family

ID=27044121

Family Applications (1)

Application Number Title Priority Date Filing Date
MA24272A MA24242A1 (fr) 1995-06-07 1996-06-06 Procede pour la preparation de nouveaux composes

Country Status (24)

Country Link
US (2) US5658903A (fr)
EP (2) EP0831830B1 (fr)
JP (1) JPH11513017A (fr)
KR (1) KR19990022574A (fr)
CN (1) CN1130358C (fr)
AT (1) ATE233561T1 (fr)
BR (1) BR9608591A (fr)
CA (1) CA2223533A1 (fr)
CZ (1) CZ392597A3 (fr)
DE (1) DE69626513T2 (fr)
DZ (1) DZ2043A1 (fr)
ES (1) ES2194106T3 (fr)
HU (1) HUP9802259A3 (fr)
IL (1) IL118544A (fr)
IN (1) IN186434B (fr)
MA (1) MA24242A1 (fr)
MY (1) MY114014A (fr)
NO (1) NO975716L (fr)
NZ (1) NZ311403A (fr)
PE (1) PE7798A1 (fr)
PL (1) PL185515B1 (fr)
TR (1) TR199701574T2 (fr)
TW (1) TW442481B (fr)
WO (1) WO1996040143A1 (fr)

Families Citing this family (197)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
WO1996021654A1 (fr) * 1995-01-12 1996-07-18 Smithkline Beecham Corporation Nouveaux composes
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
US6369068B1 (en) 1995-06-07 2002-04-09 Smithkline Beecham Corporation Amino substituted pyrimidine containing compounds
IL118544A (en) 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
ZA9610687B (en) 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
AP9700912A0 (en) * 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
BR9706973A (pt) * 1996-01-11 1999-04-06 Smithkline Beecham Corp Novos compostos de imidazol substituídos
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
WO1997032583A1 (fr) * 1996-03-08 1997-09-12 Smithkline Beecham Corporation Utilisations de composes csaidtm en tant qu'inhibiteurs de l'angiogenese
WO1997035855A1 (fr) * 1996-03-25 1997-10-02 Smithkline Beecham Corporation Nouveau traitement de lesions du systeme nerveux central
WO1997035856A1 (fr) * 1996-03-25 1997-10-02 Smithkline Beecham Corporation Nouveau traitement des lesions du systeme nerveux central
EP0956018A4 (fr) 1996-08-21 2000-01-12 Smithkline Beecham Corp Composes d'imidazole, compositions les contenant et leur utilisation
AU5147598A (en) * 1996-10-17 1998-05-11 Smithkline Beecham Corporation Methods for reversibly inhibiting myelopoiesis in mammalian tissue
ZA9711092B (en) * 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US6548512B1 (en) 1996-12-23 2003-04-15 Bristol-Myers Squibb Pharma Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US5929076A (en) * 1997-01-10 1999-07-27 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
CA2288787A1 (fr) 1997-05-22 1998-11-26 G.D. Searle And Co. Derives de pyrazole comme inhibiteurs de kinase p38
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
WO1998056377A1 (fr) 1997-06-13 1998-12-17 Smithkline Beecham Corporation Nouveaux composes de pyrazole et de pyrazoline substitues
EP0994870A4 (fr) 1997-06-19 2002-10-23 Smithkline Beecham Nouveaux composes imidazole a substitution d'aryloxypymiridine
US6339099B1 (en) 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
EP1019396A1 (fr) 1997-07-02 2000-07-19 SmithKline Beecham Corporation Nouveaux imidazoles cycloalkyle-substitues
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
AR016294A1 (es) * 1997-07-02 2001-07-04 Smithkline Beecham Corp Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
EP1041989A4 (fr) 1997-10-08 2002-11-20 Smithkline Beecham Corp Nouveaux composes substitues de cycloalcenyle
CA2316296A1 (fr) * 1997-10-10 1999-04-22 Imperial College Of Science, Technology And Medicine Emploi de composes de csaidtm pour le traitement des contractions uterines
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
IL136045A0 (en) * 1997-11-14 2001-05-20 Sankyo Co Pyridylpyrrole derivatives and pharmaceutical compositions containing the same
CA2314980A1 (fr) 1997-12-19 1999-07-01 Smithkline Beecham Corporation .0mposes d'imidazole heteroaryle substitues, leurs compositions et usages pharmaceutiques
US20080300281A1 (en) * 1997-12-22 2008-12-04 Jacques Dumas Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
US7517880B2 (en) * 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US6448257B1 (en) 1998-05-22 2002-09-10 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
US6130235A (en) * 1998-05-22 2000-10-10 Scios Inc. Compounds and methods to treat cardiac failure and other disorders
US6589954B1 (en) 1998-05-22 2003-07-08 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
US6340685B1 (en) 1998-05-22 2002-01-22 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
US6867209B1 (en) 1998-05-22 2005-03-15 Scios, Inc. Indole-type derivatives as inhibitors of p38 kinase
AU760527C (en) 1998-05-22 2004-05-06 Smithkline Beecham Corporation Novel 2-alkyl substituted imidazole compounds
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
US6207687B1 (en) * 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
DE69917296T2 (de) * 1998-08-20 2005-05-25 Smithkline Beecham Corp. Neue substituierte triazolverbindungen
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
WO2000012074A2 (fr) 1998-08-28 2000-03-09 Scios Inc. INHIBITEURS DE p38-α KINASE
EP1107957B1 (fr) 1998-08-29 2006-10-18 AstraZeneca AB Composes de pyrimidine
AU5438499A (en) 1998-08-29 2000-03-21 Astrazeneca Ab Pyrimidine compounds
WO2000026209A1 (fr) * 1998-11-03 2000-05-11 Novartis Ag 4-phenyl-5-pyrimidinyl-imidazoles anti-inflammatoires
EP1126852B1 (fr) 1998-11-04 2004-01-21 SmithKline Beecham Corporation Pyrazines substitues pyridin-4-yle ou pyrimidin-4-yle
US6239279B1 (en) 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
EP1140840B1 (fr) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. Diphenylurees a substituants -g(v)-carboxyaryles, inhibitrices de kinase raf
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7351834B1 (en) * 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE556713T1 (de) 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
UA73492C2 (en) * 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
CA2360934A1 (fr) 1999-02-22 2000-08-31 Lin-Hua Zhang Derives polycyclo heterocycliques utilises en tant qu'agents anti-inflammatoires
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
EE04799B1 (et) 1999-03-12 2007-04-16 Boehringer Ingelheim Pharmaceuticals, Inc. Ühendid, mis on kasulikud põletikuvastaste vahenditena, nende ühendite valmistamise meetodid ja neid sisaldavad farmatseutilised kompositsioonid
EP1163236B1 (fr) 1999-03-12 2005-11-09 Boehringer Ingelheim Pharmaceuticals Inc. Composes aromatiques heterocycliques utilises en tant qu'agents anti-inflammatoires
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
CO5170501A1 (es) * 1999-04-14 2002-06-27 Novartis Ag AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
RU2278115C2 (ru) * 1999-05-21 2006-06-20 Сайос Инк. ПРОИЗВОДНЫЕ ИНДОЛЬНОГО РЯДА В КАЧЕСТВЕ ИНГИБИТОРОВ p38 КИНАЗЫ
IL146309A (en) 1999-05-21 2008-03-20 Scios Inc Derivatives of the indole type and pharmaceutical preparations containing them as inhibitors of kinase p38
DE60024830T2 (de) 1999-07-09 2006-06-14 Boehringer Ingelheim Pharma Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen
US7122666B2 (en) * 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
GB9919778D0 (en) * 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
US6541477B2 (en) 1999-08-27 2003-04-01 Scios, Inc. Inhibitors of p38-a kinase
BR0014041A (pt) * 1999-09-17 2003-07-15 Smithkline Beecham Corp Utilização de csaids em infecção por rinovìrus
DE60024480T2 (de) * 1999-10-27 2006-07-27 Novartis Ag Thiazol und imidazo[4,5-b]pyridin verbindungen und ihre verwendung als pharmazeutika
ES2230171T3 (es) 1999-11-23 2005-05-01 Smithkline Beecham Corporation Compuestos 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p38 quinasa.
JP2003514900A (ja) 1999-11-23 2003-04-22 スミスクライン・ビーチャム・コーポレイション ＣＳＢＰ／ｐ３８キナーゼ阻害剤としての３，４−ジヒドロ−（１Ｈ）−キナゾリン−２−オン化合物
EP1233950B1 (fr) 1999-11-23 2005-10-05 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-ones comme inhibiteurs de csbp/p38 kinase
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
CO5261556A1 (es) * 1999-12-08 2003-03-31 Pharmacia Corp Composiciones inhibidoras de ciclooxigenasa-2 que tiene rapido acceso de efecto terapeutico
US6525046B1 (en) 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
US6608052B2 (en) 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
BR0109643A (pt) * 2000-03-30 2003-04-22 Shionogi & Co Processo sintético e forma de cristal de derivados condensados da imidazopiridina
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
US20020128267A1 (en) * 2000-07-13 2002-09-12 Rebanta Bandyopadhyay Method of using COX-2 inhibitors in the treatment and prevention of ocular COX-2 mediated disorders
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
EP2404603A1 (fr) * 2000-10-23 2012-01-11 Glaxosmithkline LLC Nouveaux composés 8H-pyrido[2,3-d]pyrimidin-7-one trisubstituté pour le traitement des maladies faisant intervenir les kinases CSBP/p38.
US6670357B2 (en) * 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6867300B2 (en) * 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
CA2429605A1 (fr) 2000-11-20 2002-05-30 Scios Inc. Inhibiteurs de la kinase p38
EP1339708A2 (fr) * 2000-11-20 2003-09-03 Scios Inc. Inhibiteurs de type indole de kinase p38
ES2279837T3 (es) 2000-11-20 2007-09-01 Scios Inc. Inhibidores de tipo piperidina/piperazina de la quinasa p38.
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US7199124B2 (en) * 2001-02-02 2007-04-03 Takeda Pharmaceutical Company Limited JNK inhibitor
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
WO2002072576A1 (fr) * 2001-03-09 2002-09-19 Pfizer Products Inc. Composes de benzimidazole anti-inflammatoires
PE20021017A1 (es) 2001-04-03 2002-11-24 Pharmacia Corp Composicion parenteral reconstituible
WO2002094267A1 (fr) * 2001-05-24 2002-11-28 Sankyo Company, Limited Preparation pharmaceutique pour prevenir ou traiter l'arthrite
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
US7076539B2 (en) * 2001-07-30 2006-07-11 Hewlett-Packard Development Company, L.P. Network connectivity establishment at user log-in
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
GB0124938D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124936D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124934D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124939D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124941D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124932D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124933D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
CA2461100C (fr) * 2001-10-22 2009-12-01 Tanabe Seiyaku Co., Ltd. Composes de 4-imidazolin-2-one
CA2466001C (fr) * 2001-10-25 2012-01-03 University Of Connecticut Materiaux bioactifs, methodes pour les produire et les utiliser
EP1439863B1 (fr) 2001-10-29 2011-01-12 Boehringer Ingelheim International GmbH Proteines homologues de mnk kinase impliquees dans la regulation de l'homeostase energetique et du metabolisme des organites
AU2003209119A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
AU2003209116A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
ATE485275T1 (de) * 2002-02-12 2010-11-15 Glaxosmithkline Llc Nicotinamide und deren verwendung als p38 inhibitoren
ES2299689T3 (es) 2002-02-25 2008-06-01 Boehringer Ingelheim Pharmaceuticals Inc. Compuestos de cicloalquil-uera fusionada con benzo 1,4-disustituido, utiles para el tratamiento de enfermedades por citoquinas.
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
AU2003208479A1 (en) 2002-03-09 2003-09-22 Astrazeneca Ab 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
BR0309669A (pt) 2002-04-23 2005-03-01 Bristol Myers Squibb Co Compostos de anilina de pirrolo-triazina úteis como inibidores de cinase
JP2005538066A (ja) 2002-07-09 2005-12-15 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規な抗コリン作用薬及びｐ３８キナーゼ阻害剤を用いた新規な医薬組成物
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
DE60309342T2 (de) 2002-08-09 2007-05-16 Eli Lilly And Co., Indianapolis Benzimidazole und benzothiazole als inhibitoren der map-kinase
US7268139B2 (en) 2002-08-29 2007-09-11 Scios, Inc. Methods of promoting osteogenesis
CA2497408A1 (fr) 2002-09-03 2004-03-18 Sarvajit Chakravarty Derives de type indole servant d'inhibiteurs de la kinase p38
UA80296C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
CN1713910A (zh) 2002-10-09 2005-12-28 西奥斯股份有限公司 作为p38激酶抑制剂的氮杂吲哚衍生物
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
GB0308201D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308186D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308185D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308466D0 (en) * 2003-04-11 2003-05-21 Novartis Ag Organic compounds
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
PT1636585E (pt) 2003-05-20 2008-03-27 Bayer Pharmaceuticals Corp Diarilureias com actividade inibidora de cinase
WO2005000298A2 (fr) * 2003-06-03 2005-01-06 Novartis Ag Inhibiteurs de p-38
HRP20110757T1 (hr) 2003-06-26 2011-11-30 Novartis Ag Inhibitori kinaze p38 bazirani na 5-članom heterociklu
US7105467B2 (en) * 2003-07-08 2006-09-12 Pharmacore, Inc. Nickel catalyzed cross-coupling reactions between organomagnesium compounds and anisole derivatives
NZ544920A (en) 2003-07-23 2009-11-27 Bayer Healthcare Llc 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
WO2005012241A2 (fr) * 2003-07-25 2005-02-10 Novartis Ag Inhibiteurs de kinase p-38
GB0318814D0 (en) * 2003-08-11 2003-09-10 Smithkline Beecham Corp Novel compounds
US7244441B2 (en) 2003-09-25 2007-07-17 Scios, Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
WO2005032481A2 (fr) 2003-09-30 2005-04-14 Scios Inc. Dérivés de quinazoline en tant que médicaments
US7419978B2 (en) * 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
US7880017B2 (en) * 2003-11-11 2011-02-01 Allergan, Inc. Process for the synthesis of imidazoles
US7183305B2 (en) * 2003-11-11 2007-02-27 Allergan, Inc. Process for the synthesis of imidazoles
US7105707B2 (en) * 2003-12-17 2006-09-12 Pharmacore, Inc. Process for preparing alkynyl-substituted aromatic and heterocyclic compounds
GB0402143D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
MY143245A (en) * 2004-04-28 2011-04-15 Mitsubishi Tanabe Pharma Corp 4- 2-(cycloalkylamino)pyrimidin-4-yl-(phenyl)-imidazolin-2-one derivatives as p38 map-kinase inhibitors for the treatment of inflammatory diseases
KR100793479B1 (ko) * 2004-04-28 2008-01-14 다나베 미츠비시 세이야꾸 가부시키가이샤 염증성 질환을 치료하기 위한 ｐ３８ ＭＡＰ- 키나제억제제로서의４-２-(시클로알킬아미노)피리딘-4-일-(페닐)-이미다졸린-2-온 유도체
CA2564325A1 (fr) * 2004-04-30 2005-11-24 Bayer Pharmaceuticals Corporation Derives de pyrazolyl uree substitues utiles dans le traitement du cancer
CA2571710A1 (fr) 2004-06-24 2006-11-02 Nicholas Valiante Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence
US7504521B2 (en) * 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
TW200618803A (en) 2004-08-12 2006-06-16 Bristol Myers Squibb Co Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
US20080051416A1 (en) * 2004-10-05 2008-02-28 Smithkline Beecham Corporation Novel Compounds
JP2006182763A (ja) * 2004-12-03 2006-07-13 Daiso Co Ltd α，β−不飽和エステルの製法
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1676574A3 (fr) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Procédé favorisant la survie des tissus ou cellules griffées
US20060178388A1 (en) * 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
GB0504753D0 (en) * 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
EP1865959A2 (fr) * 2005-03-25 2007-12-19 Glaxo Group Limited Procede de preparation de derives pyridoý2,3-d¨pyrimidin-7-one et 3,4-dihydropyrimidoý4,5-d¨pyrimidin-2(1h)-one
PE20061351A1 (es) 2005-03-25 2007-01-14 Glaxo Group Ltd COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38
US20060235020A1 (en) * 2005-04-18 2006-10-19 Soojin Kim Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein
GB0512429D0 (en) * 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
US7473784B2 (en) 2005-08-01 2009-01-06 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
DE102005048072A1 (de) * 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazole als Fungizide
US7745428B2 (en) 2005-09-30 2010-06-29 Astrazeneca Ab Imidazo[1,2-A]pyridine having anti-cell-proliferation activity
DE102006001161A1 (de) * 2006-01-06 2007-07-12 Qiagen Gmbh Verfahren zum Nachweis von Cytosin-Methylierungen
AU2007223342A1 (en) * 2006-03-07 2007-09-13 Bristol-Myers Squibb Company Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors
CA2649209A1 (fr) 2006-04-12 2007-10-18 Probiodrug Ag Inhibiteurs d'enzyme
CN101616667A (zh) 2006-10-27 2009-12-30 百时美施贵宝公司 可用作激酶抑制剂的杂环酰胺化合物
US7943617B2 (en) * 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
EP1992344A1 (fr) 2007-05-18 2008-11-19 Institut Curie P38 alpha comme cible therapeutique pour les maladies associées á une mutation de FGFR3
EP2300466B1 (fr) 2008-06-20 2014-08-06 Bristol-Myers Squibb Company Composés d'imidazopyridine et d'imidazopyrazine utilisés comme inhibiteurs de kinase
WO2009155389A1 (fr) * 2008-06-20 2009-12-23 Bristol-Myers Squibb Company Composés de triazolopyridine utilisés comme inhibiteurs de kinase
WO2012031057A1 (fr) 2010-09-01 2012-03-08 Bristol-Myers Squibb Company Bms-582949 pour le traitement d'une maladie rhumatismale résistante
CN113350352B (zh) 2015-03-23 2024-09-10 天莅生物科技私人有限公司 呼吸性疾病的治疗
AU2018262108A1 (en) * 2017-05-03 2019-11-21 The University Of Melbourne Compounds for the treatment of respiratory diseases
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
EP3692144A1 (fr) 2017-10-05 2020-08-12 Fulcrum Therapeutics, Inc. Utilisation d'inhibiteurs de p38 pour réduire l'expression de dux4
WO2020093097A1 (fr) * 2018-11-07 2020-05-14 The University Of Melbourne Composés et compositions pour le traitement de maladies respiratoires
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
US11987572B2 (en) * 2019-06-03 2024-05-21 Regents Of The University Of Minnesota Therapeutic compounds and methods of use thereof
WO2022195579A1 (fr) 2021-03-15 2022-09-22 Saul Yedgar Dipalmitoyl-phosphatidyl-éthanol-amine conjuguée à l'acide hyaluronique en combinaison avec des médicaments anti-inflammatoires non stéroïdiens (ains) pour traiter ou soulager des maladies inflammatoires

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707475A (en) * 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3929807A (en) * 1971-05-10 1975-12-30 Ciba Geigy Corp 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
US3940486A (en) * 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US4058614A (en) * 1973-12-04 1977-11-15 Merck & Co., Inc. Substituted imidazole compounds and therapeutic compositions therewith
US4199592A (en) * 1978-08-29 1980-04-22 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-2-nitroimidazoles
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
DD201677A5 (de) * 1980-07-25 1983-08-03 Ciba Geigy Verfahren zur herstellung von trisubstituierten imidazolderivaten
US4503065A (en) * 1982-08-03 1985-03-05 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl 1-2-halo imidazoles
US4565875A (en) * 1984-06-27 1986-01-21 Fmc Corporation Imidazole plant growth regulators
US4686231A (en) * 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
IL83467A0 (en) * 1986-08-15 1988-01-31 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same
EP0457727A1 (fr) * 1990-05-17 1991-11-21 Ciba-Geigy Ag Pesticides
US5252741A (en) * 1990-08-10 1993-10-12 Reilly Industries, Inc. Processes for the synthesis of imines, aldehydes, and unsymmetrical secondary amines
EP0563286A4 (en) 1990-12-13 1995-01-11 Smithkline Beecham Corp Novel csaids
WO1992010190A1 (fr) 1990-12-13 1992-06-25 Smithkline Beecham Corporation Nouveaux medicaments anti-inflammatoires suppresseurs de cytokine
JP3264492B2 (ja) 1992-01-13 2002-03-11 スミスクライン・ビーチャム・コーポレイション ピリジル置換イミダゾール
US5593992A (en) 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5593991A (en) 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
US5670527A (en) 1993-07-16 1997-09-23 Smithkline Beecham Corporation Pyridyl imidazole compounds and compositions
ZA945363B (en) 1993-07-21 1995-03-14 Smithkline Beecham Corp Novel compounds
AU693475B2 (en) * 1993-10-01 1998-07-02 Novartis Ag Pyrimidineamine derivatives and processes for the preparation thereof
US5543520A (en) * 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
CN1047776C (zh) * 1993-10-01 1999-12-29 诺瓦蒂斯有限公司 具有药理学活性的吡啶类衍生物及其制备方法
AU693114B2 (en) * 1993-10-01 1998-06-25 Novartis Ag Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof
WO1996021654A1 (fr) 1995-01-12 1996-07-18 Smithkline Beecham Corporation Nouveaux composes
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
IL118544A (en) 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them

Also Published As

Publication number Publication date
CA2223533A1 (fr) 1996-12-19
EP0831830B1 (fr) 2003-03-05
ATE233561T1 (de) 2003-03-15
IN186434B (fr) 2001-09-01
BR9608591A (pt) 1999-01-05
NO975716L (no) 1998-02-04
PL323916A1 (en) 1998-04-27
IL118544A (en) 2001-08-08
NZ311403A (en) 1999-11-29
US5658903A (en) 1997-08-19
EP0831830A1 (fr) 1998-04-01
KR19990022574A (ko) 1999-03-25
NO975716D0 (no) 1997-12-05
TW442481B (en) 2001-06-23
HUP9802259A2 (hu) 1999-09-28
AU6272696A (en) 1996-12-30
EP0831830A4 (fr) 1998-12-02
JPH11513017A (ja) 1999-11-09
EP1314728A1 (fr) 2003-05-28
DE69626513D1 (en) 2003-04-10
MY114014A (en) 2002-07-31
TR199701574T2 (xx) 1999-09-21
ES2194106T3 (es) 2003-11-16
AU699646B2 (en) 1998-12-10
WO1996040143A1 (fr) 1996-12-19
PL185515B1 (pl) 2003-05-30
HUP9802259A3 (en) 2002-02-28
DZ2043A1 (fr) 2002-10-23
US6218537B1 (en) 2001-04-17
PE7798A1 (es) 1998-03-20
CN1130358C (zh) 2003-12-10
DE69626513T2 (de) 2003-12-24
CZ392597A3 (cs) 1998-09-16
IL118544A0 (en) 1997-03-18
CN1192147A (zh) 1998-09-02

Similar Documents

Publication Publication Date Title
MA24242A1 (fr) Procede pour la preparation de nouveaux composes
PL327735A1 (en) Novel substituted derivatives of imidazole
MX9805634A (es) Compuestos novedosos de imidazol substituido.
MA23143A1 (fr) Procede pour la preparation de compositions vaccinantes .
MY116478A (en) Tri-substituted imidazoles having multiple therapeutic properties
IS4226A (is) Hliðstæðar aðferðir við framleiðslu á nýjum (R)-5-karbamóýl-8-flúor-3-N,N-tvíútskiptum-amínó-3,4-díhýdró-2H-1-bensópýrönum
UA42795C2 (uk) Протизапальний засіб для зовнішнього застосування, що містить німесулід, і спосіб його одержання
MA24158A1 (fr) Derives d'imidazole substitues, procede pour leur preparation et compositions les contenant
MA24182A1 (fr) Procede pour la preparation de 2,4-diaminopyrimidines substituees
FR2687687B1 (fr) Procede pour mesurer la taille de fragments d'adn.
FR2753911B1 (fr) Procede de preparation d'une composition antimousse encapsulee, et composition ainsi preparee
DE69120287D1 (en) Aminosulfonylharnstoff-acat-inhibitoren
FR2666334B1 (fr) Procede continu de preparation d'acrylamides et de methacrylamides n-substitues.
HUP9801056A3 (en) Triazolones as apolipoprotein-b synthesis inhibitors, process for producing them, their use and pharmaceutical compositions containing the same
AU634003B2 (en) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
FR2733227B1 (fr) Procede pour la preparation de 1,1-difluoroethane
FR2673635B1 (fr) Procede pour la preparation d'une composition aerosol.
MX9709912A (es) Compuestos de imidazol, procedimiento para prepararlos y uso de los mismos.
FR2736635B1 (fr) Procede de preparation d'alpha,omega-bromochloroalcanes
FR2718131B1 (fr) Procédé de préparation d'octadiénols.
FR2736634B1 (fr) Procede de preparation d'alpha,omega-bromochloroalcanes
EP0728485A3 (fr) Composition de traitement externe de la mycose du sabot chez les onguiculés, en particulier le cheval
GEP20022799B (en) ) Intermediates for Making HIV-Protease Inhibitors and Methods of Making HIV- Protease Inhibitors
ITPA930012A0 (it) Metodo per l'eliminazione del mal di testa.
IL140919A0 (en) N-substituted azabicycloheptane derivatives, production and use thereof